The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 842, doi. 10.1007/s10637-023-01408-w
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2023 AND VI 41 AND IP 6
Results: 11
1
2
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 834, doi. 10.1007/s10637-023-01404-0
- By:
- Publication type:
- Article
3
Gastrointestinal signet ring cell malignancy: current advancement and future prospects.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 861, doi. 10.1007/s10637-023-01403-1
- By:
- Publication type:
- Article
4
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 802, doi. 10.1007/s10637-023-01397-w
- By:
- Publication type:
- Article
5
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 787, doi. 10.1007/s10637-023-01401-3
- By:
- Publication type:
- Article
6
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 816, doi. 10.1007/s10637-023-01400-4
- By:
- Publication type:
- Article
7
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 777, doi. 10.1007/s10637-023-01399-8
- By:
- Publication type:
- Article
8
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 825, doi. 10.1007/s10637-023-01398-9
- By:
- Publication type:
- Article
9
Antitumor activity of the new tyrphostin briva against BRAF<sup>V600E</sup>-mutant colorectal carcinoma cells.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 791, doi. 10.1007/s10637-023-01402-2
- By:
- Publication type:
- Article
10
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 808, doi. 10.1007/s10637-023-01396-x
- By:
- Publication type:
- Article
11
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 6, p. 851, doi. 10.1007/s10637-023-01395-y
- By:
- Publication type:
- Article